Vaccitech reports positive final Phase 1b/2 HBV002 data; two patients achieve non-detectable HBsAg

Barinthus Biotherapeutics plc.

Two of five patients with baseline HBsAg <100 IU/mL in Group 3 developed non-detectable HBsAg, sustained eight months after last dose.
Group 3 mean HBsAg reduction 0.76 log10 at 2 months (p<0.001) and 0.98 log10 at 8 months (p<0.001).
VTP-300 monotherapy in Group 2 showed 0.7-1.4 log10 declines in three participants; robust T cell response correlated with HBsAg decline.
Phase 2b trial HBV003 >40% enrolled (48/120); interim data expected Q4 2023.
Phase 2a trial with Arbutus (VTP-300 after AB-729) in 40 patients; interim data expected Q4 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.